Latest News
Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals Inc Estimates – SWB:1T3
- Syndax Revuforj: The Best Inventions of 2026
- Syndax, Incyte bin lung fibrosis programme for Niktimvo after Phase II miss
- MAXPIRe failure ends Syndax's axatilimab program in idiopathic pulmonary fibrosis
- Syndax shares fall 17% after calling it quits on Niktimvo fibrosis program
- Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans.
- Syndax ends fibrosis program for Niktimvo after mid-stage disappointment
- Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
- Syndax Pharmaceuticals rated 'Strong Buy' on la...
- Syndax Pharmaceuticals synthesizes new menin/MLL interaction inhibitors
- Syndax Pharmaceuticals (SNDX) Stock Looks Fully Valued After Its 21% Gain
- Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts (NASDAQ:SNDX)
Headlines from the last 30 days, linking to the original publishers. See all market news →